---
title: "Cellular Senescence"
---
# Cellular Senescence
`disease · aging · cell-cycle-arrest · permanent · senescence-associated-secretory-phenotype · chronic-pathology · cancer`

Last modified 2026-05-29 · 4 papers · 5 incoming links · multi-omics-defined

| | |
|---|---|
| **Type** | Aging hallmark; regulated cell-cycle arrest |
| **Mechanism** | p38 MAPK activation; lysosomal cholesterol accumulation |
| **Key regulators** | [[pex5]], [[gpr30]], [[flt1]] |
| **Organellar dysfunction** | Peroxisomal biogenesis loss; impaired autophagy |
| **SASP drivers** | Pro-inflammatory secretory phenotype |
| **Clinical contexts** | Radioresistance, ccRCC, chronic lung disease, aging |
| **Papers** | 4 indexed |

---

**Cellular senescence** is a permanent cell-cycle arrest hallmark of aging characterized by irreversible growth inhibition and increasingly recognized as a critical driver of chronic pathology across multiple tissues. Unlike apoptosis, senescent cells remain metabolically active and exhibit a senescence-associated secretory phenotype (SASP)—a pro-inflammatory secretory program that perpetuates tissue damage and exacerbates age-related disease.¹ The condition is mechanistically centered on p38 mitogen-activated protein kinase (p38 MAPK) activation, peroxisomal dysfunction via loss of the import receptor [[pex5|PEX5]], and impaired autophagic flux, which collectively suppress key anti-senescence pathways and establish irreversible growth arrest in response to replicative or oxidative stress.

---

## Mechanism

Cellular senescence is initiated through multiple stress pathways converging on p38 MAPK signaling. Peroxisomal biogenesis is significantly downregulated in senescent cells; loss of [[pex5|PEX5]], the critical peroxisomal import receptor, activates p38 MAPK signaling and simultaneously reduces nuclear translocation of the transcription factor EB (TFEB).² This impairs autophagic flux and dysregulates metabolic homeostasis, establishing a pro-senescent cellular state. Metabolomic profiling has revealed that [[pex5|PEX5]] overexpression enhances taurine biosynthesis by facilitating peroxisomal localization of key synthetic enzymes; remarkably, exogenous taurine supplementation restores [[pex5|PEX5]] levels in senescent fibroblasts and aged tissues, establishing a positive feedback loop through which taurine acts as an anti-senescent metabolite.² The underlying mechanism integrates peroxisomal function, lysosomal cholesterol homeostasis, and metabolic remodeling, making senescence a nexus of organellar and metabolic dysregulation.

---

## Radiotherapy Resistance

Cellular senescence emerges as a critical adaptive response to ionizing radiation, rendering cancer cells resistant to further therapeutic insult. Lysosomal cholesterol accumulation during radiotherapy drives cellular senescence and suppresses the secretion of senescence-associated pro-inflammatory cytokines, a paradoxical protection against immune activation.¹ Prophylactic inhibition of cholesterol deposition via nanomedicine delivery systems (such as U@HC, which sequentially releases U18666A and β-cyclodextrin in the acidic tumor microenvironment) blocks the abnormal accumulation of lysosomal cholesterol in cancer cells, simultaneously reducing both cellular senescence and SASP signatures, thereby enhancing radiosensitization and prolonging survival.¹ This mechanism reveals senescence as a critical bottleneck in radiotherapy efficacy, positioning cholesterol metabolism as an exploitable target to overcome senescence-driven radioresistance.

---

## Senescence in Clear Cell Renal Cell Carcinoma

Elevated cellular senescence profoundly suppresses the immune microenvironment in clear cell renal cell carcinoma (ccRCC), exacerbating patient prognosis and immune evasion. Multi-omics analysis combining transcriptomic, proteomic, spatial transcriptomic, and single-cell approaches, validated through machine learning algorithms, identified [[flt1|FLT1]] as the pivotal single gene driving ccRCC progression through senescence-mediated epithelial-endothelial crosstalk.³ [[flt1|FLT1]] functions as the core hub within a regulatory network closely associated with [[vegfa|VEGFA]] and [[akt1|AKT1]]; endothelial cells expressing [[flt1|FLT1]] alone, [[akt1|AKT1]] alone, or co-expressing both show enhanced malignancy, while proximal tubular epithelial cells with elevated [[vegfa|VEGFA]] expression drive paracrine senescence escalation.³ This [[flt1|FLT1]]-centered axis reveals how cellular senescence and epithelial-endothelial crosstalk synergistically suppress anti-tumor immunity, suggesting that targeting senescence in ccRCC may restore immune surveillance and improve treatment outcomes.

---

## Aging and Chronic Lung Disease

Cellular senescence is increasingly recognized as a central driver of age-related lung pathology. In human fetal lung fibroblasts and aged mouse lungs, peroxisomal dysfunction via [[pex5|PEX5]] downregulation triggers p38 MAPK activation and impairs the synthesis of taurine, an endogenous anti-senescent metabolite.² The senescent state persists because reduced taurine biosynthesis fails to restore [[pex5|PEX5]] expression, breaking the positive feedback loop that normally maintains peroxisomal homeostasis. This mechanism explains why chronic lung diseases—characterized by progressive fibroblast senescence, impaired autophagy, and metabolic dysregulation—accumulate in aging populations and why exogenous taurine supplementation can mitigate senescence phenotypes in both cultured senescent fibroblasts and aged lungs.² Beyond the lung, dermal aging is similarly driven by senescence; D-galactose-induced senescence in human dermal fibroblasts activates pro-inflammatory cascades that promote visible signs of aging such as periorbital wrinkles and loss of dermal structural integrity.

---

## Therapeutic Strategies

Emerging pharmacological approaches target senescence through multiple mechanisms. Tranexamic acid (TXA), traditionally used for pigmentary disorders, protects human dermal fibroblasts from D-galactose-induced senescence via the [[gpr30|GPR30]]/[[p38-mapk|p38 MAPK]] signaling pathway, demonstrating anti-aging potential in topical formulations.⁴ The nanomedicine U@HC employs tumor microenvironment-responsive drug release to sequentially deliver cholesterol modulators, directly suppressing both senescence and SASP while enhancing radiotherapy efficacy.¹ At the metabolic level, taurine supplementation and [[pex5|PEX5]] restoration represent upstream anti-senescence strategies that simultaneously improve peroxisomal biogenesis, autophagic flux, and metabolic homeostasis.² Multi-omics informed discovery pipelines have positioned cellular senescence as a critical therapeutic hub, enabling the development of senescence-targeted therapies that address not only cancer radioresistance but also age-related diseases spanning pulmonary, dermal, and immune contexts.

---

## References
1. PMID:41765335 — Prophylactic sequential drug administration potentiates cancer radiotherapy by inhibiting cholesterol deposition and cellular senescence
2. PMID:41794210 — PEX5 integrates the p38 MAPK signaling pathway and taurine metabolism to regulate senescence in lung fibroblasts
3. PMID:41999263 — Multi-omics and machine learning-uncovered FLT1-mediated epithelial-endothelial crosstalk in cellular senescence driving clear cell renal cell carcinoma malignancy
4. PMID:42059427 — Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway